Partner profiles are usually a little… buttoned-up. But Visby Medical isn’t exactly a buttoned-up company. It’s the kind of outfit that looked at the traditional PCR lab workflowexpensive instruments, trained techs, long turnaround timesand said: “Cool. What if we put that in your hand and made it work in 30 minutes?”

In 2025, that “what if” became a very real “oh wow.” Between FDA milestones, CLIA-waived point-of-care progress, and an accelerating at-home “test-to-treat” ecosystem, Visby Medical spent the year turning fast molecular diagnostics from a nice-to-have into something partners can actually build programs aroundclinically, operationally, and commercially.

This 2025 Partner Profile breaks down what Visby is, what changed in 2025, and where partnersfrom women’s health clinics to digital health platformscan plug in (without needing a PhD in logistics or a second mortgage for capital equipment).

2025 Snapshot: The Year Visby “Graduated” From Interesting to Infrastructure

• OTC at-home molecular testing got real. In March 2025, the FDA granted marketing authorization for the Visby Medical Women’s Sexual Health Testan at-home, over-the-counter test for chlamydia, gonorrhea, and trichomoniasis that delivers results in about 30 minutes via an app.
• Point-of-care respiratory testing broadened. Visby also announced FDA 510(k) clearance and a CLIA waiver for a rapid PCR respiratory panel that detects and differentiates Flu A, Flu B, and SARS-CoV-2.
• Pipeline momentum in men’s sexual health. In 2025, Visby advanced a men’s sexual health test designed for CLIA-waived settings, reflecting expansion beyond women’s health into broader STI diagnostics.
• Capital + scaling. Mid-2025 financing supported manufacturing scale-up and distribution acceleration for at-home STI testingan unglamorous but essential ingredient for partners who need dependable supply.
• Distribution and ecosystem growth. Late 2025 and into early 2026, consumer access expanded through major channels (including large lab networks and consumer testing platforms), signaling a partner-first approach to reach.

Translation: in 2025, Visby didn’t just ship “a cool test.” It built the scaffolding that lets partners deliver faster diagnosis, faster treatment, and better patient experienceswithout waiting for a lab to call them back days later.

Who Is Visby Medical?

Visby Medical is an infectious disease diagnostics company founded in 2012 with a focus on making PCR testing faster and more accessible. The company’s platform centers on single-use, palm-sized PCR tests designed to deliver results in under 30 minutesaiming to reduce dependence on centralized labs for time-sensitive decisions.

Visby’s big idea is deceptively simple: no separate analyzer, no complicated calibration, no “please schedule your follow-up.” The device is designed to handle the molecular heavy lifting, while software (including a companion app for at-home testing) handles user guidance and results reporting.

For partners, that platform approach matters because it supports multiple product “lanes”:

• At-home OTC testing (consumer-directed, privacy-forward, app-enabled)
• Point-of-care (POC) testing in CLIA-waived or clinical settings (workflow-friendly, fast results)
• Menu expansion into other infectious disease panels (respiratory now; additional conditions in development)

Why 2025 Was a Breakout Year for Visby’s Partner Value

1) FDA Marketing Authorization Opened the Door for True At-Home STI PCR

At-home STI testing isn’t new. What’s new is at-home PCR testing with results in about 30 minutes, performed entirely at home, and available over the counter. In March 2025, the FDA authorized Visby’s Women’s Sexual Health Test for chlamydia, gonorrhea, and trichomoniasispositioning it as the first diagnostic test for these infections that can be purchased without a prescription and performed entirely at home.

From a partner perspective, this shifts the conversation from “nice consumer gadget” to “clinically meaningful on-ramp.” The FDA’s messaging around earlier diagnosis, reduced spread, and decreased anxiety about seeking care underscores why access and speed matter in sexual health.

2) CLIA-Waived Respiratory PCR Created a Practical Use Case for Urgent Care and Clinics

Respiratory season is when operational pain shows up with a megaphone. Waiting a day (or three) for results can mean unnecessary antibiotics, missed antivirals, delayed isolation decisions, and patient dissatisfactionespecially when symptoms overlap.

Visby’s Respiratory Health Test received FDA 510(k) clearance and a CLIA waiver in February 2025 for detecting and differentiating Flu A, Flu B, and SARS-CoV-2. That combinationPCR + CLIA waiver + multiplex respiratory targetshits a sweet spot for partners who manage high visit volume and need quick answers in the exam room.

3) Funding + Manufacturing Scale Is a Partner Feature (Even If It’s Not Sexy)

Partners don’t just need clinical performancethey need consistent supply, predictable fulfillment, and pricing that won’t make finance teams faint. In June 2025, Visby announced a financing round (approximately $55M with potential up to $65M) aimed at accelerating launch and distribution of its at-home women’s STI test and supporting operational scale.

For partners, “manufacturing scale-up” is code for: we can run real programs, not just pilots. It’s also how new categories survive the leap from headline to habit.

The Product Portfolio Partners Care About

Visby Women’s Sexual Health Test (OTC At-Home)

This is the flagship at-home product that changed Visby’s trajectory in 2025. Key partner-relevant characteristics include:

• Targets: chlamydia, gonorrhea, and trichomoniasis
• Sample type: self-collected vaginal swab
• Turnaround time: results in approximately 30 minutes
• Delivery of results: app-enabled reporting, with guidance and next-step support
• Clinical implications: antibiotics can treat these infections, but delayed diagnosis can contribute to complications (including infertility risk when infections go untreated)

Why partners like it: it reduces “care friction.” Patients can test quickly and privately, while partner ecosystems (telehealth, lab networks, women’s health platforms, employers) can route positives into appropriate care pathways.

Visby Sexual Health Testing in Point-of-Care Settings (CLIA-Waived)

Visby’s broader sexual health footprint includes point-of-care testing that’s designed for speed and ease-of-use in clinical settings. Earlier generations in women’s sexual health received FDA clearance and CLIA waiver, and 2025 continued that momentum with expansion efforts and additional tests.

In practical terms, that means a clinic can potentially:

• test during a visit,
• reduce empiric treatment and retesting,
• and close the loop before the patient disappears into the “I’ll check my portal later” abyss.

Visby Men’s Sexual Health Test (POC / CLIA-Waived Direction)

Men’s sexual health testing is operationally different (specimen type, care settings, and patient behavior all shift). In 2025, Visby advanced a Men’s Sexual Health Test intended for use with male urine specimens in CLIA-waived settings, reflecting product expansion beyond women-focused pathways.

For partners, the opportunity is straightforward: men are often under-tested, and faster results make it easier to treat promptly, notify partners, and reduce transmissionespecially in urgent care, campus health, and community clinics.

Visby Respiratory Health Test (POC / CLIA-Waived)

This is the “winter workhorse” category: Flu A, Flu B, and SARS-CoV-2 differentiation in a rapid PCR format. Partners who benefit most tend to be:

• urgent care chains managing surges,
• primary care practices trying to keep visits efficient,
• retail clinics balancing throughput and accuracy,
• employers and universities needing fast decision-making for outbreaks.

The differentiator isn’t just speedit’s what speed enables: earlier antivirals when appropriate, reduced unnecessary antibiotics, fewer “just in case” follow-ups, and better patient satisfaction.

Market Reality Check: Why Partners Are Leaning Into Faster STI and Respiratory Diagnostics

Partners don’t adopt new diagnostics because the technology is neat. They adopt because the market hurts.

The STI burden is still substantial

STIs remain widespread in the U.S., with millions of cases reported annually. CDC reporting has highlighted how access barriers and delayed diagnosis contribute to transmission and complications. In sexual health, speed is not a vanity metric; it’s a clinical lever.

When infections can be asymptomatic, the “I’ll wait and see” strategy is basically an invitation for complicationsand for ongoing spread. Faster testing helps shift behavior from avoidance to action.

Respiratory symptoms are overlappingand operationally expensive

Most patients don’t walk into urgent care saying, “Hello, I believe I have influenza A, subtype unknown.” They say: “I feel terrible.” Multiplex respiratory testing helps clinicians answer the question that matters: what should we do now?

Where Visby Fits in a Partner Ecosystem

Think of Visby’s partner opportunities as three layers: access, care routing, and trust.

1) Access Partners

• Consumer testing platforms that want a differentiated at-home product with fast results
• Large lab networks that can offer consumer-directed testing while connecting patients into care
• Retail and last-mile delivery networks that reduce friction and increase completion rates

2) Care Routing Partners (“Test-to-Treat”)

• Telehealth providers who can turn a positive result into timely counseling and treatment
• Women’s health apps and care navigation platforms that serve users across fertility, pregnancy, and preventive care journeys
• Health plans and employer programs that want earlier intervention and fewer costly complications

3) Trust + Infrastructure Partners

• Cloud and digital infrastructure providers supporting secure app experiences and scalable care journeys
• Provider organizations seeking clinical-grade diagnostics without laboratory bottlenecks

In late 2025, Visby leaned into this ecosystem approach by expanding distribution via direct-to-consumer partners and integrating digital care supportsignals that the company sees partnerships as the go-to-market engine, not an afterthought.

Partner Playbook: How to Integrate Visby Without Breaking Your Workflow

Step 1: Pick the “job to be done”

Start with one high-impact use case:

• Reduce time-to-treatment for STIs in women’s health
• Increase testing completion rates for populations that avoid clinics
• Improve respiratory differential diagnosis during surge season

Step 2: Decide where results will live (and who sees them)

At-home models often route results to an app, while clinical settings may route results through existing workflows. Partners should define:

• how users receive results,
• how positives get connected to care,
• how privacy expectations are communicated (especially in sexual health),
• and how follow-up is handled when symptoms persist despite negative results.

Step 3: Build a clean care pathway for positives

For STI testing, partners often succeed when they remove “decision fatigue.” A great pathway answers:

• Where does the patient go for treatment (telehealth, clinic, pharmacy)?
• How are prescriptions handled?
• What patient education is delivered (and when)?
• How do you handle retesting guidance and partner notification counseling?

Step 4: Measure the outcomes partners actually care about

• Completion rate: how many purchased tests get used?
• Time-to-treatment: how long from result to therapy?
• Reduction in follow-up visits: fewer “return for results” appointments?
• Patient satisfaction: especially around privacy and speed

In other words: don’t just count testscount what the tests unlock.

Practical Considerations and “Fine Print” Partners Should Respect

No partner profile is complete without the realities that keep clinicians and compliance teams happy:

• False positives/false negatives happen. As with many diagnostics, inaccurate results can occur and can delay appropriate care or lead to unnecessary treatment. Partners should have clear guidance for next steps, especially if symptoms persist or exposure risk is high.
• Positive results need medical follow-up. Testing is the start, not the finish. Build care routing that’s fast and patient-friendly.
• Privacy and data handling must be explicit. Sexual health is high-sensitivity territory. Partners should align messaging, consent flows, and user expectations from day one.
• Operational readiness matters. Customer support, replacement policies, shipping timelines, and clear instructions are part of the clinical experience in at-home testingwhether you like it or not.

Why Partners Choose Visby in 2025 (In One Sentence)

Because it brings lab-grade PCR speed to places labs don’t livethe exam room, the urgent care front desk, and yes, the bathroom counterwhile creating real partnership surfaces for distribution, care navigation, and digital health integration.

And in a healthcare environment that’s allergic to friction, that’s not just a feature. It’s a strategy.

Partner Experiences: What It Feels Like to Build With Visby (Composite Stories)

Note: The vignettes below are composite “day-in-the-life” experiences based on common partner workflows in women’s health, urgent care, and digital health. They’re designed to be realistic, not to describe any single organization’s confidential operations.

Experience #1: The Women’s Health Clinic That Finally Stops Losing Patients to the “Later” Pile

Before adding rapid PCR options into its ecosystem, a women’s health clinic lived in a familiar loop: patients came in for symptoms (or concern after a new partner), samples went out, results came back later, and the clinic chased follow-ups like it was an unpaid side hustle. Some patients picked up calls. Some didn’t. Some started treatment days later. Some never didespecially when symptoms were mild or nonexistent. That’s how silent infections win.

When the clinic partnered with a digital care pathway that supported at-home testing, something changed: the moment of motivation stayed connected to action. Patients could test privately without rearranging their schedules, and positive results didn’t just land like a scary emailthey routed into telehealth or clinic follow-up with clear next steps. The staff noticed fewer “where are my results?” calls, fewer phone-tag marathons, and a measurable drop in missed follow-up opportunities. The biggest surprise wasn’t the tech; it was the behavior shift. People who would never book a second appointment were suddenly willing to complete a care plan when it was fast, discreet, and obvious.

Experience #2: The Urgent Care Operator Who Learns That Speed Is a Revenue Saver, Not a Luxury

An urgent care group doesn’t have time for diagnostic suspense. During respiratory season, every visit is a traffic jam of overlapping symptoms. When results take too long, clinicians hedge. That can mean more “just in case” prescriptions, more return visits, and a waiting room that moves like molasses.

After adding rapid multiplex respiratory PCR into its point-of-care workflow, the group’s operational manager described the shift as “less guessing, more doing.” Clinicians gained confidence to treat flu when appropriate, counsel clearly when COVID was detected, and avoid unnecessary therapies when results didn’t support them. The front desk noticed fewer angry “why didn’t anyone tell me?” calls. Nurses appreciated that patient education got easier because it was anchored to a concrete result. And leadership liked the economics: faster decisions reduced downstream churn and helped the clinics maintain throughput without sacrificing clinical rigor. In urgent care, that’s basically a miracleserved with a side of fewer complaints.

Experience #3: The Digital Health Product Team That Stops Treating Testing Like a Dead-End Button

Digital health platforms often struggle with a painful truth: a “Get tested” button doesn’t automatically create a completed test, a result, or treatment. One women’s health app team described their original testing flow as “a fancy door that opened into a hallway with no lights.” Users clicked, ordered a kit, waited, mailed a sample, waited again, and thenbest casegot results days later. Engagement dropped at every step.

With rapid at-home PCR, the product team could redesign the entire journey around immediacy. They built onboarding that matched real user emotions (anxiety, urgency, privacy concerns), provided step-by-step guidance, andmost importantlyconnected results to care without forcing users to hunt for options. The team watched completion rates improve because the process felt finite: swab, run, get results, act. They also learned to treat privacy and tone as product features, not legal footnotes. In sexual health, language matters. A calm, clear experience can be the difference between someone getting treated promptly and someone closing the app and trying to forget they ever opened it.

Taken together, these partner experiences point to the same lesson: Visby’s 2025 value proposition isn’t just rapid PCRit’s rapid PCR that partners can wrap into an end-to-end experience that people actually complete.

The post Visby Medical: 2025 Partner Profile appeared first on Blobhope Family.